CTLA4 and neoplasm: We provided direct evidence that additional blockade of α-PD-1 overcame tumour ‘escape' from α-CTLA-4 monotherapy and resulted in complete tumour rejection with long-lasting protective immunity to re-challenge, which is predominantly T-cell-dependent and natural killer (NK)/natural killer T (NKT) cell-independent.